Altered histamine H 3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases

British Journal of Pharmacology

Volumn 157, Issue 1, 2009, Pages 118-129

  Jin, C Y ^a,b   Anichtchik, O ^a,b,c   Panula, P ^a,b  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bipolar disorder; Cognition; Hippocampal formation; Histamine h 3 receptor; Major depression; Prefrontal cortex; Schizophrenia; Temporal cortex

Indexed keywords

HISTAMINE H3 RECEPTOR; RADIOLIGAND;

ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; DENTATE GYRUS; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; LIGAND BINDING; MAJOR DEPRESSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; SCHIZOPHRENIA; SUBICULUM; TEMPORAL CORTEX; ADULT; AGED; BRAIN; DEPRESSION; FEMALE; MALE; METABOLISM; MIDDLE AGED; RADIOASSAY; TEMPORAL LOBE;

ADULT; AGED; BIPOLAR DISORDER; BRAIN; DEPRESSION; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; RADIOLIGAND ASSAY; RECEPTORS, HISTAMINE H3; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 67149133755     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00149.x     Document Type: Article

References (61)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Alves-Rodrigues A, Leurs R, Willems E, Timmerman H (1996). Binding of Clozapine metabolites and analogues to the histamine H3 receptor in rat brain cortex. Arch Pharm (Weinheim) 329: 413-41.6. (Pubitemid 26334436)
3. 3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis 8: 707-716.
4. Bacciottini L, Passani B, Mannaioni P, Blandina P (2001). Interactions between histaminergic and cholinergic systems in learning and memory. Behav Brain Res 124: 183-194. (Pubitemid 32964637)
5. Bakker RA, Lozada AL, van Marie A, Shenton FC, Drutel G, Karlstedt K et al. (2006). Discovery of naturally occurring splice variants of the rat histamine H3 receptor that act as dominant-negative isoforms. Mol Pharmacol 69: 1194-1206.
6. Browman KE, Komater VA, Curzon P, Rueter LE, Hancock AA, Decker MW et al. (2004). Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behave Brain Res 153: 69-76. (Pubitemid 38829290)
7. Cangioli I, Baldi E, Mannaioni PF, Bucherelli C, Blandina P, Passani MB (2002). Activation of histaminergic H3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release. Eur J Neurosci 16: 521-528. (Pubitemid 35471871)
8. Chen Z, Shen YJ (2002). Effects of brain histamine on memory deficit induced by nucleus basalis-lesion in rats. Acta Pharmacol Sin 23: 66-70. (Pubitemid 34073271)
9. Chikai T, Oishi R, Saeki K (1993). Microdialysis study of sedative drugs on extracellular histamine in the striatum of freely moving rats. J Pharmacol Exp Ther 266: 1277-1281. (Pubitemid 24175769)
10. Coge F, Guenin SP, Audinot V, Renouard-Try A, Beauverger P, Macia C et al. (2001). Genomic organization and characterization of splice variants of the human histamine H3 receptor. Biochem J 355: 279-288. (Pubitemid 32397785)
11. Damasio AR (1989). Time-locked multiregional retroactivation: a system level proposal fro the neural substances of recall and recognition. Cognition 33: 25-62.
12. Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M, Collins JP Jr, Wyatt RJ (1993). Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 16: 518-524. (Pubitemid 23344764)
13. Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT (1999). G protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 73: 1121-1126. (Pubitemid 29395470)
14. Eastwood SL, Harrison PJ (2000). Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Mol Psychiatry 5: 425-432.
15. Eidi M, Zarrindast MR, Eidi A, Oryan S, Parivar K (2003). Effects of histamine and cholinergic systems on memory retention of passive avoidance learning in rats. Eur J Pharmacol 465: 91-96.
16. Faganello FR, Medalha CC, Mattioli R (2003). Haloperidol and chlorpheniramine interaction in inhibitory avoidance in goldfish. Behav Brain Res 147: 83-88.
17. Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghih R et al. (2002). Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131: 151-161. (Pubitemid 34143166)
18. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB et al. (2005). Pharmacological properties of ABT-239 [4-(2-(2-[(2R)-2- Methylpyrrolidinyl]ethyl.)-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. Pharmacol Exp Ther 13: 176-190.
19. Frisch C, Hasenöhrl RU, Krauth J, Huston JP (1998). Anxiolytic-like behaviour after lesion of the tuberomammillary nucleus E2-region. Exp Brain Res 119: 260-264. (Pubitemid 28098519)
20. 3 receptors in the rat cortex. Brain Res 690:104-107.
21. Ghi P, Ferretti C, Orsetti M (2001). Cognitive enhancing properties of thioperamide infused into the nucleus basalis magnocellularis of the rat. Inflamm Res 50: S78-S79. (Pubitemid 32452977)
22. Gur RE, Cowell PE, Ltshaw A, Turetsky BI, Grossman RI, Arnold SE et al. (2000). Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch Gen Psychiatry 57: 761.-768.
23. Haas HL, Panula P (2003). The role of histamine and the tuberomamillary nucleus in the brain. Nat Rev Neurosci 4: 121-130.
24. Ikarashi Y, Yuzurihara M (2002). Experimental anxiety induced by histaminergics in mast cell-deficient and congenitally normal mice. Pharmacol Bilchem Behav 72: 437-441. (Pubitemid 34251356)
25. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA (2000). Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Boil Psychiatry 48: 641-650.
26. Jin CY, Panula P (2005). The laminar histamine receptor system in human prefrontal cortex suggests multiple levels of histaminergic regulation. Neuroscience 132: 137-149.
27. Jin CY, Kalimo H, Panula P (2002). The histaminergic system in human thalamus: correlation of innervation to receptor expression. Eur J Neurosci 15: 1125-1138. (Pubitemid 35463614)
28. Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M (1990). Effect of famotidine on deficit symptoms of schizophrenia. Lancet 335: 1351-1352. (Pubitemid 20186429)
29. Kathmann M, Schlicker E, Gothert M (1994). Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. Psychopharmacology (Berl) 116: 464-468. (Pubitemid 24374248)
30. Knable MB, Torrey EF, Webster MJ, Bartko JJ (2001). Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 55: 651-659.
31. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF (2004). Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 9: 609-620. (Pubitemid 38850441)
32. Kobayashi RM, Kopin IJ (1974). The effect of stress and environmental lighting on histamine in the rat brain. Brain Res 74: 356-359.
33. Law AJ, Harrison PJ (2003). The distribution and morphology of prefrontal cortex pyramidal neurons identified using antineurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J Psychiatric Res 37: 487-499.
34. Liu L, Schulz SC, Lee S, Reutiman TJ, Fateml SH (2007). Hippocampal CA1. pyramidal cell size is reduced in bipolar disorder. Cell Mol Neurobiol 27: 351-358. (Pubitemid 46763882)
35. Malmberg-Aiello P, Ipponi A, Bartolini A, Schunack W (2002). Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors. Pharmacol Biochem Behav 71: 321-326. (Pubitemid 34102494)
36. Martinez-Mir MI, Pollard H, Moreau J, Traiffort E, Ruat M, Schwartz JC et al. (1993). Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 15: 209-220. (Pubitemid 23339513)
37. Mazurkiewickz-Kwilecki IM (1979). Single and repeated air blast stress and brain histamine. Pharmacol Biochem Behav 12: 35-39.
38. Mazurkiewickz-Kwilecki IM, Prell GD (1986). Brain histamine response to stress in 12 month old rats. Life Sci 38: 2339-2345.
39. Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, Mita T et al. (1991). Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 30: 349-356.
40. Oishi R, Nishibori M, Itoh Y, Saeki K (1986). Diazepan-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol 124: 337-342. (Pubitemid 16090474)
41. Oishi R, Itoh Y, Saeki K (1992). Inhibition of histamine turnover by 8-OH-DPAT, buspirone and 5-hydroxytryptophan in the mouse and rat brain. Naunyn Schmiedebergs Arch Pharmacol 345: 495-499.
42. Oliveira RMW, Guimarães FS, Deakin JFW (2008). Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 41: 333-341. (Pubitemid 351761067)
43. 3-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task. Behav Brain Res 124: 235-242.
44. Oyewumi LK, Vollick D, Merskey H, Plumb C (1994). Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci 19: 145-150. (Pubitemid 24131865)
45. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P (2004). The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25: 618-625. (Pubitemid 39458167)
46. Pérez-García C, Morales L, Cano MV, Sancho I, Alguacil LF (1999). Effects of histamine H3 rceptor ligands in experimental models of anxiety and depression. Psychopharmacology (Berl) 142: 215-220. (Pubitemid 29190858)
47. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG et al. (1995). Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14: 93-104.
48. Rodrigues AA, Jansen FP, Leurs R, Timmerman H, Prell GD (1995). Interaction of clozapine with the histamine H3 receptor in rat brain. Br J. f Pharmacol 114: 1523-1524.
49. Rosse RB, Kendrick K, Tsui LC, Fay-McCarthy M, Collins JP Jr., Rosenberg, P et al. (1995). Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin Neuropharmacol 18: 369-374.
50. Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC et al. (1996). An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 19: 341-348. (Pubitemid 26250117)
51. Santos NR, Huston JP, Brandão ML (2003). Blockade of histamine H2 receptors of the periaqueductal gray and inferior colliculus induces fear-like behaviors. Pharmacol Biochem Behav 75: 25-33.
52. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001). A review of MRI findings in schizophrenia. Schizophr Res 49: 1-52.
53. Taylor KM, Snyder SH (1971). Brain histamine: rapid apparent turnover altered by restraint and cold stress. Science 172: 1037-1039.
54. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000). The Stanley foundation brain collection and neuropathology consortium. Schizophr Res 44: 151-155. (Pubitemid 30411930)
55. Tregellas JR, Shatti S, Tanabe JL, Martin LF, Gibson L, Wylie K et al. (2007). Gray matter volume differences and the effects of smoking on gray matter in schizophrenia. Schizophr Res 97: 242-249. (Pubitemid 350088396)
56. Van der Goot H, Timmerman H (2000). Selective ligands as tools to study histamine receptors. Eur f Med Chem 35: 5-20. (Pubitemid 30136684)
57. Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR, Weiner DM (2002). Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacology 42: 929-940. (Pubitemid 34632680)
58. 3H]Nalpha-methylhistamine binding differ from that of rodents. Eur J Pharmacol 377: 233-239.
59. Yanai K, Son LZ, Endou M, Sakurai E, Nakagawasai O, Tadano T et al. (1998). Behavioral characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience 87: 479-487. (Pubitemid 28370904)
60. Yoshitomi I, Itoh Y, Oishi R, Saeki K (1986). Brain histamine turnover enhanced by foot shock. Brain Res 362: 195-198. (Pubitemid 16185442)
61. Yuzurihara M, Ikarashi Y, Ishige A, Sasaki H, Kuribara H, Maruyama Y (2000). Effects of drugs acting as histamine releasers or histamine receptor blockers on an experimental anxiety model in mice. Pharmacol Biochem Behav 67: 145-150.